Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study

BACKGROUND An increased risk of insulin resistance (IR) has been identified in rheumatoid arthritis (RA), a chronic inflammatory disorder with elevated levels of pathogenic cytokines. Biologics targeting proinflammatory cytokines can control the disease and improve insulin sensitivity in RA. Although Janus kinase (JAK) signaling can regulate cytokine receptors and participate in RA pathogenesis, it remains to be elucidated whether there is a reduction of IR in such patients under JAK inhibitor (JAKi) therapy. AIM To study the effect of JAKi treatment on the reduction of IR in RA patients with active disease. METHODS A retrospective study was carried out from April 1, 2017 to March 31, 2021 in a population of non-diabetic patients with active RA who were undergoing tofacitinib (TOF) therapy with 5 mg twice-daily immediate-release formulation. RESULTS Fifty-six RA patients, aged 30 years to 75 years (mean +/- SD: 52.3 +/- 11.1) with disease activity score 28 values ranging from 4.54 to 7.37 (5.82 +/- 0.74), were classified into high-IR (> 2.0) and low-IR (>= 2.0) groups based on their baseline homeostatic model assessment (HOMA)-IR levels. They had no previous exposure to JAKi, and received TOF therapy for no less than 6 mo. In 30 patients who were naive to biologics, after a 24-week therapeutic period, the high-IR group showed reduced HOMA-IR levels (3.331 +/- 1.036 vs 2.292 +/- 0.707, P < 0.001). In another 26 patients who were exposed to tumor necrosis factor-alpha or interleukin-6 blockers, the high-IR group, despite having achieved a decrease but with lower magnitude than in naive patients, showed reduced HOMA-IR levels (2.924 +/- 0.790 vs 2.545 +/- 1.080, P = 0.018). CONCLUSION In this retrospective study, reduced IR was achieved in non-diabetic active RA patients following 24 wk of TOF therapy.

Automated summary

In this retrospective study, a reduction of insulin resistance was achieved in non-diabetic active RA patients following 24 weeks of TOF therapy.